IRIDEX Corporation cannot accurately predict the impact to glaucoma probes and system sales that will result from the reimbursement changes of the five LCDs as customers and prospects evaluate their usage of probes and system purchases. Given this uncertainty, guidance for 2023 has been withdrawn as the impact to Cyclo G6 system and probe sales is evaluated further.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.85 USD | -0.35% | -5.94% | +1.42% |
Mar. 26 | Transcript : IRIDEX Corporation, Q4 2023 Earnings Call, Mar 26, 2024 | |
Mar. 26 | Earnings Flash (IRIX) IRIDEX CORPORATION Reports Q4 Revenue $12.5M, vs. Street Est of $14.9M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.42% | 46.48M | |
+7.15% | 220B | |
+6.60% | 183B | |
+9.86% | 133B | |
+24.32% | 107B | |
-0.95% | 63.05B | |
+11.04% | 51.74B | |
+4.81% | 50.47B | |
-1.43% | 40.91B | |
+24.40% | 31.91B |
- Stock Market
- Equities
- IRIX Stock
- News IRIDEX Corporation
- IRIDEX Corporation Withdraws Previously Announced Guidance for 2023